The purpose of the study is to see if this imaging method can help classify the progression of diabetic kidney disease. Participants in the study will receive injections of these substances and undergo MRI scans to assess kidney function. The study will look at how well the kidneys are working by measuring things like metabolism and blood flow in the kidneys. The study will also check how reliable the imaging method is by repeating the scans to see if the results are consistent.

Throughout the study, participants will be monitored to ensure their safety and to gather information on how their kidneys are functioning. The study aims to provide new insights into diabetic kidney disease and potentially improve how this condition is diagnosed and monitored in the future.

The purpose of the study is to understand how blood platelets, which help with clotting, behave in people with Type 1 Diabetes compared to healthy individuals. The study will also look at the presence of plaques, which are fatty deposits in the arteries, and how they relate to blood clotting in people with diabetes. Participants will be observed over a period of time to see if aspirin affects these factors and if it can predict changes in artery health or the risk of heart disease.

Participants will be monitored for changes in their blood clotting and artery health, with some taking aspirin for at least seven days. The study will also investigate the relationship between blood clotting and inflammation, which is the body’s response to injury or infection, in people with Type 1 Diabetes. The trial aims to provide insights into how these factors might predict future health outcomes related to heart and blood vessel health.

The purpose of the study is to see how well these medications can be used together to improve kidney health in people with Type 2 Diabetes. Participants will take either Empagliflozin or Finerenone, or a combination of both, in the form of film-coated tablets. The study will be conducted remotely, meaning participants can take part from their own homes using digital technologies. This approach aims to make it easier for people to participate without needing to visit a clinic frequently.

Throughout the study, participants will be asked to provide urine samples and monitor their blood pressure and body weight. The study will last for several weeks, and participants will be asked to take their medication as directed. The researchers will collect information on how participants feel about taking part in a remote trial and how well they adhere to the treatment plan. The study will also look at changes in kidney function, blood pressure, and blood sugar levels to understand the effects of the medications better.

The purpose of the study is to determine if the combination of these two medications is more effective in reducing a specific measure related to kidney function, known as the urinary albumin-to-creatinine ratio, than taking either medication alone. Participants in the study will be randomly assigned to one of three groups: one group will receive both finerenone and empagliflozin, another group will receive only finerenone, and the third group will receive only empagliflozin. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient.

The study will last for about six months, during which participants will take the assigned medication daily. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to gather information on the safety and effectiveness of the treatment combination, which could lead to better management of chronic kidney disease in people with type 2 diabetes.

Participants in the study will receive either the R3R01 tablet or a placebo, which is a substance with no active medication. The study will last for 12 weeks, during which time participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also involve the use of a special solution called Technescan DTPA, which is injected to help measure kidney function.

The main goal is to see if R3R01 can lower the amount of albumin in the urine compared to the placebo. Additionally, the study will look at other factors such as kidney function and blood pressure. This research aims to provide new insights into managing diabetic kidney disease and improving treatment options for patients.